Avery's Bucket List: Parents pen blog for baby dying of spinal muscular atrophy

Repligen has reported positive results from Phase I study of RG3039 for the potential treatment of spinal muscular atrophy (SMA). The blinded, ascending, single dose study demonstrated that RG3039 was well tolerated at all doses administered and showed

Repligen has reported positive results from Phase I study of RG3039 for the potential treatment of spinal muscular atrophy (SMA). The blinded, ascending, single dose study demonstrated that RG3039 was well tolerated at all doses administered and showed

Repligen licensed RG3039 in 2009 from Families of Spinal Muscular Atrophy (FSMA), a patient advocacy organization that funded and directed the preclinical devel.

Repligen licensed RG3039 in 2009 from Families of Spinal Muscular Atrophy (FSMA), a patient advocacy organization that funded and directed the preclinical devel.

Repligen licensed RG3039 in 2009 from Families of Spinal Muscular Atrophy (FSMA), a patient advocacy organization that funded and directed the preclinical development of RG3039 with an investment of more than $13 million.

Make your Wordpress site into a cash making device by means of WP a wordpress plugin directory plugins.